Adage Capital Partners
OVID icon

Adage Capital Partners’s Ovid Therapeutics OVID Stock Holding History

Adage Capital Partners’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.7M Buy
6,163,781
+2,671,781
+77% +$4.78M 0.02% 597
2025
Q4 		$5.69M Buy
3,492,000
+2,142,000
+159% +$3.3M 0.01% 744
2025
Q3 		$1.75M Buy
1,350,000
+200,000
+17% +$173K ﹤0.01% 814
2025
Q2 		$379K Hold
1,150,000
– – ﹤0.01% 816
2025
Q1 		$359K Buy
1,150,000
+150,000
+15% +$92.2K ﹤0.01% 818
2024
Q4 		$934K Buy
+1,000,000
New +$1.12M ﹤0.01% 821

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Adage Capital Partners's OVID Position: Q1 2026 in Review

Adage Capital Partners increased its Ovid Therapeutics (OVID) stake by 77% in Q1 2026, buying an estimated $4.78M and bringing the position to 6,163,781 shares worth $13.7M. The position accounts for 0.02% of the portfolio, ranked #597.

Adage Capital Partners first reported a position in OVID in Q4 2024 and has held it in 6 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Adage Capital Partners held 6,163,781 shares of Ovid Therapeutics worth $13.7M as of Q1 2026.
  • Adage Capital Partners bought 2,671,781 Ovid Therapeutics shares in Q1 2026, an estimated $4.78M.
  • Ovid Therapeutics made up 0.02% of Adage Capital Partners's portfolio in Q1 2026, its #597 holding.
  • Adage Capital Partners first reported a position in Ovid Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.